Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells

Radotinib, developed as a BCR/ABL tyrosine kinase inhibitor (TKI), is approved for the second-line treatment of chronic myeloid leukemia (CML) in South Korea. However, therapeutic effects of radotinib in acute myeloid leukemia (AML) are unknown. In the present study, we demonstrate that radotinib si...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: Heo, Sook-Kyoung, Noh, Eui-Kyu, Yoon, Dong-Joon, Jo, Jae-Cheol, Choi, Yunsuk, Koh, SuJin, Baek, Jin Ho, Park, Jae-Hoo, Min, Young Joo, Kim, Hawk
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4466365/
https://ncbi.nlm.nih.gov/pubmed/26065685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0129853
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak